Intellia.jpg
Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
October 07, 2024 07:30 ET | Intellia Therapeutics, Inc.
NTLA-2002 is a single-dose treatment designed to prevent potentially life-threatening swelling attacks in people with hereditary angioedema (HAE)NTLA-2002 is Intellia’s second in vivo candidate to...
Intellia.jpg
Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions
October 01, 2024 07:30 ET | Intellia Therapeutics, Inc.
New data to be presented will include biomarkers of disease progression and functional capacity from the ongoing Phase 1 study of nex-z, an investigational in vivo CRISPR gene editing therapy for ATTR...
Intellia.jpg
Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting
September 12, 2024 07:30 ET | Intellia Therapeutics, Inc.
First presentation of detailed Phase 2 results following previous positive topline announcement that study of NTLA-2002 met primary and all secondary endpoints Intellia to host investor webcast on...
Logo.png
Halberd Partnership Secures Contract from Defense Atomics Corporation to Address Brain Injury and PTSD
September 11, 2024 08:00 ET | Halberd Corp.
Halberd Partnership Secures Contract from Defense Atomics Corporation to Address Brain Injury and PTSD
Caribou_logo.png
Caribou Biosciences Announces the FDA has Granted Fast Track Designations to CB-010 in Refractory SLE and to CB-012 in Relapsed or Refractory AML
September 03, 2024 08:00 ET | Caribou Biosciences, Inc.
-- Fast Track designation is designed to expedite clinical development and regulatory review timelines -- -- Additional FDA designation for CB-010 following earlier RMAT and Fast Track...
Global CRISPR Gene Editing Market
CRISPR Gene Editing Market Size Projected to Surpass $2 Billion by 2024 Amid Increasing Demand for Genetic Treatments - Long-term Forecast to 2028 and 2033
August 15, 2024 09:57 ET | Research and Markets
Dublin, Aug. 15, 2024 (GLOBE NEWSWIRE) -- The "Global CRISPR Gene Editing Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The CRISPR gene editing market has...
tina-albertson
Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer
August 12, 2024 08:00 ET | Caribou Biosciences, Inc.
-- Highly-experienced hematologist and oncologist with proven track record successfully driving global clinical development of CAR-T cell therapies -- BERKELEY, Calif., Aug. 12, 2024 (GLOBE...
22157.jpg
CRISPR Cas9 Market and Clinical Trials Report to 2029: CRISPR-Cas9 Therapy Clinical Trials By Company, County, Indication & Phase
August 12, 2024 04:52 ET | Research and Markets
Dublin, Aug. 12, 2024 (GLOBE NEWSWIRE) -- The "CRISPR Cas9 Market Opportunity & Clinical Trials Outlook 2029" report has been added to ResearchAndMarkets.com's offering. The global landscape...
Caribou_logo.png
Caribou Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update
August 06, 2024 16:05 ET | Caribou Biosciences, Inc.
-- Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases; clinical data reports planned for 2024 and H1 2025 -- -- Enrolling 2L LBCL and prior CD19 relapsed LBCL...
22157.jpg
CRISPR Technology Research Report 2024 | Now Available
August 06, 2024 09:08 ET | Research and Markets
Dublin, Aug. 06, 2024 (GLOBE NEWSWIRE) -- The "CRISPR Technology Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The crispr technology market size has grown...